Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)

Brain, Behavior, and Immunity

Volumn 23, Issue 2, 2009, Pages 240-250

  Hutchinson, Mark R ^a,b   Lewis, Susannah S ^a   Coats, Benjamen D ^a   Skyba, David A ^c   Crysdale, Nicole Y ^a   Berkelhammer, Debra L ^a   Brzeski, Anita ^a   Northcutt, Alexis ^a   Vietz, Christine M ^d   Judd, Charles M ^a   Maier, Steven F ^a   Watkins, Linda R ^a   Johnson, Kirk W ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c TOURO UNIVERSITY NEVADA   (United States)

^d Thermo Fisher Scientific   (United States)

^e Avigen Inc   (United States)

Author keywords

Astrocyte; Microglia; Morphine; Neuron; Oxycodone

Indexed keywords

CELL MARKER; CHEMOKINE; CXCL1 CHEMOKINE; CYTOKINE; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBUDILAST; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MALLINCKRODT; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MORPHINE; NALOXONE; NEURITE PROMOTING FACTOR; NEUROTROPHIC FACTOR; OPIATE; OXYCODONE; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NUCLEUS; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; GLIA CELL; HYPERACTIVITY; INFLAMMATION; MALE; MORNING DOSAGE; MORPHINE ADDICTION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; ANTI-BACTERIAL AGENTS; BRAIN; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MALE; MINOCYCLINE; MORPHINE; NALOXONE; OPIOID-RELATED DISORDERS; OXYCODONE; PAIN; PAIN MEASUREMENT; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; WEIGHT LOSS;

EID: 58849159101     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2008.09.012     Document Type: Article

References (78)

1. Alonso E., Garrido E., Diez-Fernandez C., Perez-Garcia C., Herradon G., Ezquerra L., Deuel T.F., and Alguacil L.F. Yohimbine prevents morphine-induced changes of glial fibrillary acidic protein in brainstem and alpha(2)-adrenoceptor gene expression in hippocampus. Neurosci. Lett. 412 (2007) 163-167
2. Andjelkov N., Elvenes J., Martin J., and Johansen O. Opiate regulation of IL-1beta and TNF-alpha in cultured human articular chondrocytes. Biochem. Biophys. Res. Commun. 333 (2005) 1295-1299
3. Azar M.R., Ahmed S.H., Lintz R., Gutierrez T., Stinus L., and Koob G.F. A non-invasive gating device for continuous drug delivery that allows control over the timing and duration of spontaneous opiate withdrawal. J. Neurosci. Methods 135 (2004) 129-135
4. Baumeister A.A., Anticich T.G., Hebert G., Hawkins M.F., and Nagy M. Evidence that physical dependence on morphine is mediated by the ventral midbrain. Neuropharmacology 28 (1989) 1151-1157
5. Baumeister A.A., Richard A.L., Richmond-Landeche L., Hurry M.J., and Waguespack A.M. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome. Neuropharmacology 31 (1992) 835-841
6. Bhatt S., Bhatt R., Zalcman S.S., and Siegel A. Role of IL-1 beta and 5-HT2 receptors in midbrain periaqueductal gray (PAG) in potentiating defensive rage behavior in cat. Brain. Behav. Immun. 22 (2008) 224-233
7. Bozarth M.A. Physical dependence produced by central morphine infusions: an anatomical mapping study. Neurosci. Biobehav. Rev. 18 (1994) 373-383
8. Calvino B., Lagowska J., and Ben-Ari Y. Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rat. Brain. Res. 177 (1979) 19-34
9. Carmody J. Avoiding fallacies in nociceptive measurements. Pain 63 (1995) 136
10. Carrigan K.A., Saurer T.B., Ijames S.G., and Lysle D.T. Buprenorphine produces naltrexone reversible alterations of immune status. Int. Immunopharmacol. 4 (2004) 419-428
11. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
12. Colloier H.O. Drug dependence: a pharmacological analysis. Br. J. Addict. Alcohol Other Drugs 67 (1972) 277-286
13. Cui Y., Liao X.X., Liu W., Guo R.X., Wu Z.Z., Zhao C.M., Chen P.X., and Feng J.Q. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain. Behavior. and Immunity 22 (2008) 114-123
14. Dafny N. Interferon modifies morphine withdrawal phenomena in rodents. Neuropharmacology 22 (1983) 647-651
15. Dame J.B., Christensen R.D., and Juul S.E. The distribution of granulocyte-macrophage colony-stimulating factor and its receptor in the developing human fetus. Pediatr Res 46 (1999) 358-366
16. Dougherty P.M., Pellis N.R., and Dafny N. The brain and the immune system: an intact immune system is essential for the manifestation of withdrawal in opiate addicted rats. Neuroscience 36 (1990) 285-289
17. Doverty M., Somogyi A.A., White J.M., Bochner F., Beare C.H., Menelaou A., and Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 93 (2001) 155-163
18. 2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50 (2005) 91-106
19. Fdez Espejo E., Cador M., and Stinus L. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score". Psychopharmacology 122 (1995) 122-130
20. Fishbain D.A., Rosomoff H.L., and Rosomoff R.S. Drug abuse, dependence, and addiction in chronic pain patients. Clin. J. Pain 8 (1992) 77-85
21. Foley T.E., Greenwood B.N., Day H.E., Koch L.G., Britton S.L., and Fleshner M. Elevated central monoamine receptor mRNA in rats bred for high endurance capacity: implications for central fatigue. Behav. Brain Res. 174 (2006) 132-142
22. Garrido E., Perez-Garcia C., Alguacil L.F., and Diez-Fernandez C. The alpha2-adrenoceptor antagonist yohimbine reduces glial fibrillary acidic protein upregulation induced by chronic morphine administration. Neurosci. Lett. 383 (2005) 141-144
23. Gellert V.F., and Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205 (1978) 536-546
24. Happel C., Steele A.D., Finley M.J., Kutzler M.A., and Rogers T.J. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. J Leukoc Biol 83 (2008) 956-963
25. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
26. Holguin A., Frank M.G., Biedenkapp J.C., Nelson K., Lippert D., Watkins L.R., Rudy J.W., and Maier S.F. Characterization of the temporo-spatial effects of chronic bilateral intrahippocampal cannulae on interleukin-1beta. J. Neurosci. Methods 161 (2007) 265-272
27. Huitinga I., van der Cammen M., Salm L., Erkut Z., van Dam A., Tilders F., and Swaab D. IL-1beta immunoreactive neurons in the human hypothalamus: reduced numbers in multiple sclerosis. J Neuroimmunol 107 (2000) 8-20
28. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., and Watkins L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World Journal 7 (2007) 98-111
29. Hutchinson M.R., Coats B.D., Lewis S.S., Zhang Y., Sprunger D.B., Rezvani N., Baker E.M., Jekich B.M., Wieseler J.L., Somogyi A.A., Martin D., Poole S., Judd C.M., Maier S.F., and Watkins L.R. Proinflammatory cytokines oppose opioid induced acute and chronic analgesia. Brain Behav. Immun. 22 (2008) 1178-1189
30. Johnston I.N., Milligan E.D., Wieseler-Frank J., Frank M.G., Zapata V., Campisi J., Langer S., Martin D., Green P., Fleshner M., Leinwand L., Maier S.F., and Watkins L.R. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. 24 (2004) 7353-7365
31. Kiefer R., and Kreutzberg G.W. Gamma interferon-like immunoreactivity in the rat nervous system. Neuroscience 37 (1990) 725-734
32. Ledeboer A., Hutchinson M.R., Watkins L.R., and Johnson K.W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 16 (2007) 935-950
33. Ledeboer A., Liu T., Shumilla J.A., Mahoney J.H., Vijay S., Gross M.I., Vargas J.A., Sultzbaugh L., Claypool M.D., Sanftner L.M., Watkins L.R., and Johnson K.W. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 21 (2007) 279-291
34. Ledeboer A., Sloane E.M., Milligan E.D., Frank M.G., Mahony J.H., Maier S.F., and Watkins L.R. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115 (2005) 71-83
35. Li Y., Barger S.W., Liu L., Mrak R.E., and Griffin W.S. S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 74 (2000) 143-150
36. Liang D., Shi X., Qiao Y., Angst M.S., Yeomans D.C., and Clark J.D. Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain 4 (2008) 7
37. Limiroli E., Gaspani L., Panerai A.E., and Sacerdote P. Differential morphine tolerance development in the modulation of macrophage cytokine production in mice. J Leukoc Biol 72 (2002) 43-48
38. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
39. Maldonado R., Stinus L., Gold L.H., and Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261 (1992) 669-677
40. Messmer D., Hatsukari I., Hitosugi N., Schmidt-Wolf I.G., and Singhal P.C. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human dendritic cells and enhances T cell activation. Mol Med 12 (2006) 284-290
41. Milligan E.D., O'Connor K.A., Nguyen K.T., Armstrong C.B., Twining C., Gaykema R.P., Holguin A., Martin D., Maier S.F., and Watkins L.R. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 21 (2001) 2808-2819
42. Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N., and Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46 (2004) 404-411
43. Mork A., and Geisler A. A comparative study on the effects of tetracyclines and ltium on the cyclic AMP second messenger system in rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 157-160
44. Nakagawa T., Fujio M., Ozawa T., Minami M., and Satoh M. Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice. Behav. Brain Res. 156 (2005) 233-239
45. Nakagawa T., and Satoh M. Involvement of glial glutamate transporters in morphine dependence. Ann N Y Acad Sci 1025 (2004) 383-388
46. Niwa M., Nitta A., Yamada K., and Nabeshima T. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci 104 (2007) 116-121
47. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., Noda Y., and Nabeshima T. Tumor necrosis factor-alpha and its inducer inhibit morphine-induced rewarding effects and sensitization. Biol Psychiatry 62 (2007) 658-668
48. Nutile-McMenemy N., Elfenbein A., and Deleo J.A. Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression. J. Neurochem. 103 (2007) 2035-2046
49. Olsson T., Kristensson K., Ljungdahl A., Maehlen J., Holmdahl R., and Klareskog L. Gamma-interferon-like immunoreactivity in axotomized rat motor neurons. J Neurosci 9 (1989) 3870-3875
50. Ozawa T., Nakagawa T., Sekiya Y., Minami M., and Satoh M. Effect of gene transfer of GLT-1, a glutamate transporter, into the locus coeruleus by recombinant adenoviruses on morphine physical dependence in rats. Eur J Neurosci 19 (2004) 221-226
51. Ozawa T., Nakagawa T., Shige K., Minami M., and Satoh M. Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res 905 (2001) 254-258
52. Patel N.A., Romero A.A., Zadina J.E., and Chang S.L. Chronic exposure to morphine attenuates expression of interleukin-1 beta in the rat hippocampus. Brain Res 712 (1996) 340-344
53. Pochon N.A., Menoud A., Tseng J.L., Zurn A.D., and Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 9 (1997) 463-471
54. Pourpak Z., Ahmadiani A., and Alebouyeh M. Involvement of interleukin-1beta in systemic morphine effects on paw oedema in a mouse model of acute inflammation. Scand J Immunol 59 (2004) 273-277
55. Punch L.J., Self D.W., Nestler E.J., and Taylor J.R. Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray. J Neurosci 17 (1997) 8520-8527
56. Raghavendra V., Tanga F.Y., and DeLeo J.A. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29 (2004) 327-334
57. Renauld A.E., and Spengler R.N. Tumor necrosis factor expressed by primary hippocampal neurons and SH-SY5Y cells is regulated by alpha(2)-adrenergic receptor activation. J Neurosci Res 67 (2002) 264-274
58. Rock R.B., Hu S., Sheng W.S., and Peterson P.K. Morphine stimulates CCL2 production by human neurons. J Neuroinflammation 3 (2006) 32
59. Roy S., Balasubramanian S., Sumandeep S., Charboneau R., Wang J., Melnyk D., Beilman G.J., Vatassery R., and Barke R.A. Morphine directs T cells toward T(H2) differentiation. Surgery 130 (2001) 304-309
60. Shavit Y., Wolf G., Goshen I., Livshits D., and Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 115 (2005) 50-59
61. Shoemaker W.J., Kosten T.A., and Muly S.M. Ethanol attenuation of morphine dependence: comparison to dizocilpine. Psychopharmacology (Berl) 134 (1997) 83-87
62. Sibinga N.E., and Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Annu Rev Immunol 6 (1988) 219-249
63. Song P., and Zhao Z.Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 39 (2001) 281-286
64. Stirling D.P., Koochesfahani K.M., Steeves J.D., and Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 11 (2005) 308-322
65. Suzumura A., Ito A., Yoshikawa M., and Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 837 (1999) 203-212
66. Trafton C.L., and Marques P.R. Effects of septal area and cingulate cortex lesions on opiate addiction behavior in rats. J Comp Physiol Psychol 75 (1971) 277-285
67. Tremblay E.C., and Charton G. Anatomical correlates of morphine-withdrawal syndrome: differential participation of structures located within the limbic system and striatum. Neurosci Lett 23 (1981) 137-142
68. Trujillo K.A. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology (Berl) 151 (2000) 121-141
69. Van Crugten J.T., Somogyi A.A., Nation R.L., and Reynolds G. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. Pain 71 (1997) 199-205
70. Wang H.L., Zhao Y., Xiang X.H., Wang H.S., and Wu W.R. Blockade of ionotropic glutamatergic transmission in the ventral tegmental area attenuates the physical signs of morphine withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1079-1087
71. Wang J., Barke R.A., Charboneau R., and Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 174 (2005) 426-434
72. Wang J., Barke R.A., and Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 282 (2007) 7164-7171
73. Watkins L.R., Hutchinson M.R., Milligan E.D., and Maier S.F. "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 56 (2007) 148-169
74. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Sci USA 95 (1998) 15769-15774
75. Zalcman S.S., and Siegel A. The neurobiology of aggression and rage: role of cytokines. Brain Behav Immun 20 (2006) 507-514
76. Zhang B., Yang L., Konishi Y., Maeda N., Sakanaka M., and Tanaka J. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 42 (2002) 262-269
77. Zhang J., and De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 97 (2006) 772-783
78. Zhang R.X., Li A., Liu B., Wang L., Ren K., Zhang H., Berman B.M., and Lao L. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 135 (2008) 232-239